MoonLake Immunotherapeutics (MLTX)

MLTX Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	26.05	22.32	23.01	21.66
Research & Development	52.36	31.8	42.05	12.64
Operating Expenses	78.4	54.12	65.06	34.29
Operating Income	-78.4	-54.12	-65.06	-34.29
Currency Exchange Gain (Loss)	-0.23	0.15	0.33	-0.07
Other Non Operating Income (Expenses)	20.61	9.99	0.27	-0
EBT Excluding Unusual Items	-58.02	-43.98	-64.47	-34.37
Other Unusual Items	-	-	-	-30
Pretax Income	-58.02	-43.98	-64.47	-64.37
Income Tax Expense	0.22	0.09	0.04	0.01
Earnings From Continuing Operations	-58.24	-44.08	-64.51	-64.37
Minority Interest in Earnings	3.44	8.07	14.53	-
Net Income	-54.8	-36.01	-49.97	-64.37
Net Income to Common	-54.8	-36.01	-49.97	-64.37
Shares Outstanding (Basic)	60	49	29	8
Shares Outstanding (Diluted)	60	49	29	8
Shares Change (YoY)	49.62%	67.30%	274.47%	-
EPS (Basic)	-0.92	-0.73	-1.70	-8.21
EPS (Diluted)	-0.92	-0.73	-1.70	-8.21
Free Cash Flow	-64.93	-43.06	-55.91	-42.27
Free Cash Flow Per Share	-1.09	-0.88	-1.90	-5.39
EBITDA	-78.35	-54.11	-65.05	-34.29
D&A For EBITDA	0.06	0.01	0.01	0.01
EBIT	-78.4	-54.12	-65.06	-34.29

Source: S&P Capital IQ. Standard template. Financial Sources.